Risk of prostate cancer associated with benign prostate disease: a primary care case-control study

被引:5
|
作者
Buckley, Brian S. [1 ]
Lapitan, Marie Carmela M. [1 ]
Simpson, Colin R. [1 ]
Sheikh, Aziz [1 ]
机构
[1] Univ Philippines Manila, Dept Surg, Philippine Gen Hosp, Manila, Philippines
来源
BRITISH JOURNAL OF GENERAL PRACTICE | 2011年 / 61卷 / 592期
关键词
URINARY-TRACT SYMPTOMS; GENERAL-PRACTICE; HYPERPLASIA; DIAGNOSIS; MEN;
D O I
10.3399/bjgp11X606573
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Benign diseases of the prostate are common in the general male population, and prostate cancer is the most common cancer in men. Uncertainty as to the nature of the association between benign and malignant disease is a source of concern for patients and clinicians. Aim To determine the likelihood of men with benign prostate disease developing prostate cancer compared with men without disease. Design Incident matched case-control study Method All incident cases of prostate cancer (n = 984) were identified in a nationally representative community-based population, and each was matched by age with two controls with no prostate cancer (n = 1968). Participants' records of the previous 5 years were searched for diagnoses of benign prostate disease. Analyses investigated an a priori hypothesis that clinicians may record disease as benign until proven to be malignant, causing misleading significant associations between benign and malignant diagnoses. Results There was a significant association between a diagnosis of prostate cancer and a benign diagnosis at any time in the previous 5 years: odds ratio (OR) 1.57 (95% confidence interval [CI] = 1.32 to 1.88). However, there was no significant association when benign diagnoses within 6 months and within 12 months of cancer diagnoses were excluded: OR 1.19 (95% CI = 0.97 to 1.46) and OR 1.00 (95% CI = 0.79 to 1.27) respectively. Conclusion Findings from this study suggest that unless prostate cancer is detected within 6 months, men diagnosed for the first time with benign disease are at no greater risk of prostate cancer than those with no recorded prostate disease.
引用
收藏
页码:e684 / e691
页数:2
相关论文
共 50 条
  • [31] Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study
    Jan Hrbacek
    Michael Urban
    Eva Hamsikova
    Ruth Tachezy
    Vaclav Eis
    Marek Brabec
    Jiri Heracek
    BMC Cancer, 11
  • [32] Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study
    Hrbacek, Jan
    Urban, Michael
    Hamsikova, Eva
    Tachezy, Ruth
    Eis, Vaclav
    Brabec, Marek
    Heracek, Jiri
    BMC CANCER, 2011, 11
  • [33] Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study
    Kerri Beckmann
    Hans Garmo
    Bertil Lindahl
    Lars Holmberg
    Pär Stattin
    Jan Adolfsson
    J. Kennedy Cruickshank
    Mieke Van Hemelrijck
    Prostate Cancer and Prostatic Diseases, 2020, 23 : 527 - 533
  • [34] Blood fatty acid patterns are associated with prostate cancer risk in a prospective nested case-control study
    Yang, Meng
    Ayuningtyas, Azalea
    Kenfield, Stacey A.
    Sesso, Howard D.
    Campos, Hannia
    Ma, Jing
    Stampfer, Meir J.
    Chavarro, Jorge E.
    CANCER CAUSES & CONTROL, 2016, 27 (09) : 1153 - 1161
  • [35] Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study
    Kaapu, Kalle J.
    Ahti, Janne
    Tammela, Teuvo L. J.
    Auvinen, Anssi
    Murtola, Teemu J.
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (05) : 1187 - 1195
  • [36] Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study
    Beckmann, Kerri
    Garmo, Hans
    Lindahl, Bertil
    Holmberg, Lars
    Stattin, Par
    Adolfsson, Jan
    Cruickshank, J. Kennedy
    Van Hemelrijck, Mieke
    PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (03) : 527 - 533
  • [37] Serum steroids in relation to prostate cancer risk in a case-control study (Greece)
    Signorello, LB
    Tzonou, A
    Mantzoros, CS
    Lipworth, L
    Lagiou, P
    Hsieh, CC
    Stampfer, M
    Trichopoulos, D
    CANCER CAUSES & CONTROL, 1997, 8 (04) : 632 - 636
  • [38] A case-control study of selenium in nails and prostate cancer risk in British men
    Allen, NE
    Morris, JS
    Ngwenyama, RA
    Key, TJ
    BRITISH JOURNAL OF CANCER, 2004, 90 (07) : 1392 - 1396
  • [39] Plasma and dietary carotenoids, and the risk of prostate cancer: A nested case-control study
    Wu, KN
    Erdman, JW
    Schwartz, SJ
    Platz, EA
    Leitzmann, M
    Clinton, SK
    DeGroff, V
    Willett, WC
    Giovannuci, E
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2004, 13 (02) : 260 - 269
  • [40] Residential greenness and risk of prostate cancer: A case-control study in Montreal, Canada
    Demoury, Claire
    Thierry, Benoit
    Richard, Hugues
    Sigler, Brittany
    Kestens, Yan
    Parent, Marie-Elise
    ENVIRONMENT INTERNATIONAL, 2017, 98 : 129 - 136